Inhibition in the cerebral cortex is essential for regulating cortical excitability and plasticity and is mediated by gamma-amino butyric acid receptors (GABAR). Two principle forms of GABARs exist: GABAARs and GABABRs which mediate short-lasting vs. long-lasting inhibitory postsynaptic potentials, respectively, and are activated by different ligands. The GABAARs can be divided into subtypes of alpha-1 6 subunit bearing receptors which are located on different populations of highly specialized inhibitory interneurons and which are responsible for different functions: for example, activation of the alpha-1 GABAAR has sedative and anticonvulsant effects while activation of the alpha-2 GABAAR results in anxiolytic effects. Classical benzodiazepines (such as diazepam) have high affinity to alpha-1, -2, -3 and -5 GABAARs, zolpidem has highest affinity to the alpha-1 GABAAR, low-doses of ethanol activate alpha-4 and -6 GABAARs in the cerebellum and baclofen is a specific GABABR agonist. Transcranial magnetic stimulation (TMS) allows testing of motor cortical inhibition. Two protocols are available which measure GABAAR mediated short-interval intracortical inhibition (SICI) and GABABR mediated long-interval intracortical inhibition (LICI). Accordingly, classical benzodiazepines enhance SICI while baclofen increases LICI. More advanced pharmacological testing of SICI with classical benzodiazepines vs. zolpidem showed that SICI is most likely mediated by the alpha-2 GABAAR. Therefore, TMS offers the opportunity to measure motor cortical inhibition mediated by the various subtypes of the GABAR. This is of strong interest for drug development, but also for measuring disordered inhibition in neurological or psychiatric diseases such as epilepsy or schizophrenia. This special lecture will provide an upto-date overview on the neuropharmacology of intracortical inhibition as measured by TMS and its clinical and research applications.